JPH01290673A - Novel substance k3543r1, its use and production - Google Patents
Novel substance k3543r1, its use and productionInfo
- Publication number
- JPH01290673A JPH01290673A JP11978688A JP11978688A JPH01290673A JP H01290673 A JPH01290673 A JP H01290673A JP 11978688 A JP11978688 A JP 11978688A JP 11978688 A JP11978688 A JP 11978688A JP H01290673 A JPH01290673 A JP H01290673A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- strain
- medium
- production
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 241000187747 Streptomyces Species 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 229940041514 candida albicans extract Drugs 0.000 abstract description 3
- 239000008103 glucose Substances 0.000 abstract description 3
- 239000012138 yeast extract Substances 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000049 pigment Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 1
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229930188887 Lactoquinomycin Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NYJGMJFBEVSQNN-CNRHASOASA-N Medermycin Chemical compound C1[C@@H](N(C)C)[C@H](O)[C@@H](C)O[C@H]1C1=CC=C(C(=O)C=2[C@H]3OC(=O)C[C@H]3O[C@H](C)C=2C2=O)C2=C1O NYJGMJFBEVSQNN-CNRHASOASA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔発明の背景〕
本発明は新規物質に、さらに詳しくはストレブトミセス
に属する菌株に3543株によって生産される抗腫瘍性
を有する新規物質に3543R1に、関する。DETAILED DESCRIPTION OF THE INVENTION [Background of the Invention] The present invention relates to a novel substance, and more particularly to 3543R1, a novel substance having antitumor properties produced by the 3543 strain belonging to Strebtomyces.
抗腫瘍物質に関してはすでに多数のものが医薬として実
用化されている。一般に化学物質の生理活性はその化学
構造に依存するところが大きいため、抗腫瘍性を有する
新規な化合物に対しては不断の希求があると言えよう。Many antitumor substances have already been put into practical use as medicines. In general, the physiological activity of a chemical substance largely depends on its chemical structure, so it can be said that there is a constant desire for new compounds with antitumor properties.
本発明は上記の希求に応えるものである。 The present invention meets the above needs.
ずなイ)ち、本発明による新規物質に3543R1は、
次の一般式(I)で示されるものである。Zunai) Among the new substances according to the present invention, 3543R1 is
It is represented by the following general formula (I).
本発明は、この酸付加塩にも関する。The invention also relates to this acid addition salt.
本発明は、また、この物質の使用に関する。The invention also relates to the use of this substance.
すなわち、本発明による抗腫瘍剤は、次式(I)で示さ
れる化合物に3543R1またはその酸付加塩をH効成
分とするものである。That is, the antitumor agent according to the present invention contains 3543R1 or an acid addition salt thereof as an H-active ingredient in the compound represented by the following formula (I).
本発明は、さらにまた、この物質の製造法に関する。The invention furthermore relates to a method for producing this material.
すなわち、本発明による次式(I)で示されるに354
3R1の製造法は、ストレプトミセス属に属し、K35
43R1の生産能を白′する菌株を適当な培地で好気的
に培養し、培養物よりに3543R1を得ることを特徴
とするものである。That is, according to the present invention, as shown by the following formula (I), 354
The production method for 3R1 is based on K35, which belongs to the genus Streptomyces.
This method is characterized in that a strain exhibiting the ability to produce 43R1 is aerobically cultured in an appropriate medium, and 3543R1 is obtained from the culture.
新規物質に3543R1
1)化学構造
本発明による新規物質に3543R1は、前記の式(I
)で示される化学構造をHする。これらの化学構造は、
次のようにして決定されたものである。3543R1 as a new substance 1) Chemical structure 3543R1 as a new substance according to the present invention has the above formula (I
) is the chemical structure shown by H. These chemical structures are
It was determined as follows.
K3543R1のプロトン核磁気共鳴スペクトル(第3
図)および炭素13核磁気共鳴スペクトル(第4図)は
ラクトキノマイシン(l aetoqulno−myc
in ) (N、 Tanaka et
al、、 J、 Ant4bioties3B、
1327−1338 (I985))のスペクトルに類
似している。スペクトルのさらに詳細な検討およびマス
スペクトルと元素分析より導かれた分子式からに354
3R1の構造を図(I)のように決定した。Proton nuclear magnetic resonance spectrum of K3543R1 (3rd
Figure 4) and carbon-13 nuclear magnetic resonance spectra (Figure 4) of lactoquinomycin
in) (N, Tanaka et
al,, J, Ant4bioties3B,
1327-1338 (I985)). From a more detailed examination of the spectrum and the molecular formula derived from the mass spectrum and elemental analysis, 354
The structure of 3R1 was determined as shown in Figure (I).
2)物理化学的性状
(I)外観 赤色粉末
(2)融点 105−110℃(分解)(3)溶解性
メタノール、エタノール、アセトン、酢酸エチル、クロ
ロホルムに可溶、ヘキサンに難溶、水に不溶。2) Physicochemical properties (I) Appearance Red powder (2) Melting point 105-110℃ (decomposition) (3) Solubility
Soluble in methanol, ethanol, acetone, ethyl acetate, chloroform, sparingly soluble in hexane, insoluble in water.
(4)Rf値(メルク社製[シリカゲル60F254」
使用)
クロロホルム−メタノール(I0: 1) 0. 25
クロロホルム−メタノール−濃アンモニア水(20+2
:0.1) 0.56(5)FD7
ススベクトル(m/z)414(M十H)”
第1図に示す。(4) Rf value (manufactured by Merck [Silica gel 60F254]
Use) Chloroform-methanol (I0: 1) 0. 25
Chloroform-methanol-concentrated ammonia water (20+2
:0.1) 0.56(5)FD7
Soot vector (m/z) 414 (M+H)” is shown in FIG.
264 (310) 、323 (I01) 、425
(I06)、494 (I26)(メタノール中)26
8 (294) 、320 (I11) 、424(9
3) 、498 (I22)(0,01規定塩酸−メタ
ノール中)
268 (308) 、330 (I07) 、531
(I22)(0,01規定水酸化ナトリウム−メタノー
ル中)
(7)赤外吸収スペクトル(KBrディスク法)第2図
に示す。264 (310), 323 (I01), 425
(I06), 494 (I26) (in methanol) 26
8 (294), 320 (I11), 424 (9
3), 498 (I22) (0.01N hydrochloric acid in methanol) 268 (308), 330 (I07), 531
(I22) (0.01N sodium hydroxide in methanol) (7) Infrared absorption spectrum (KBr disk method) shown in FIG.
(8)プロトン核磁気共鳴スペクトル(500メガヘル
ツ、重クロロホルム中)第3図に示す。(8) Proton nuclear magnetic resonance spectrum (500 MHz, in deuterated chloroform) shown in FIG.
(9)炭素13核磁気共鳴スペクトル(I25メガヘル
ツ、重クロロホルム中)第4図に示す。(9) Carbon-13 nuclear magnetic resonance spectrum (I25 MHz, in deuterated chloroform) is shown in FIG.
本発明による化合物は、分子中に塩基性のアミノ基をH
しているので、酸付加塩の形で存在しうる。このような
酸付加塩を形成するのに用いうる酸としては、例えば、
塩酸、硫酸、リン酸等の無機酸、あるいは酢酸、酒石酸
、プロピオン酸、クエン酸、コハク酸等の有機酸が包含
される。The compound according to the present invention has a basic amino group in the molecule.
Therefore, it can exist in the form of acid addition salts. Examples of acids that can be used to form such acid addition salts include:
Inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, and organic acids such as acetic acid, tartaric acid, propionic acid, citric acid, and succinic acid are included.
K3543R1の製造
概要
化合物に3543R1は現在のところ微生物の項五によ
ってのみ得られているが、類縁化合物の合成化学的修飾
によって製造することも、あるいは全合成化学的に製造
することもできよう。Overview of the production of K3543R1 The compound 3543R1 has currently been obtained only by microorganisms, but it may be produced by synthetic chemical modification of related compounds or by total synthetic chemistry.
微生物の培養による場合の菌株としてはストレプトミセ
ス属に属するに3543R1生産能を有するものが使用
される。具体的には、本発明者らの分離したストレプト
ミセス・タナシェンシスに3543株かに3543R1
を生産することが本発明者らによって明らかにされてい
るが、その他の菌株については、抗生物質生産菌単離の
常法によって適当なものを自然界より分離することが可
能である。また、ストレプトミセス・タナシェンシスに
3543株を含めてに3543R1の生産菌を放射線照
射その他の変異処理に付して、K3543R1の生産能
を高める余地も残されている。さらに、遺伝子工学が発
展した現今では、K3543株のに3543R1生産遺
伝子を利用した遺伝子工学的手法によるに3543R1
の生産も可能である。When culturing a microorganism, a strain belonging to the genus Streptomyces and having the ability to produce 3543R1 is used. Specifically, 3543 strain Kani 3543R1 was added to Streptomyces thanashensis isolated by the present inventors.
Although the present inventors have shown that antibiotic-producing strains produce antibiotics, it is possible to isolate suitable strains from nature using conventional methods for isolating antibiotic-producing bacteria. Furthermore, there is still room to increase the K3543R1 production ability by subjecting 3543R1 producing bacteria, including the 3543 strain of Streptomyces thanashensis, to irradiation or other mutational treatments. Furthermore, now that genetic engineering has developed, 3543R1 can be produced using genetic engineering techniques that utilize the 3543R1 production gene of the K3543 strain.
It is also possible to produce
K3543株
に3543R1生成能を有するストレプトミセス属の菌
株として本発明者らの見出しているに3543株は、下
記の内容のものである。The K3543 strain found by the present inventors as a Streptomyces strain having the ability to produce 3543R1 is as follows.
1゜ 由来および寄託番号
に3543株は中華人民共和国で採取した土壌から分離
されたものであり、昭和63年3月5Bに工業技術院微
生物工業技術研究所に寄託されて[微工研菌寄第992
2号J (FERM P−9922)の番号を得て
いる。1゜ Strain 3543 in terms of origin and deposit number was isolated from soil collected in the People's Republic of China, and was deposited at the Institute of Microbial Technology, Agency of Industrial Science and Technology on March 5B, 1986. No. 992
It has a number of No. 2 J (FERM P-9922).
2、 菌学的性状 に3543株の菌学的性状は以下のとおりである。2. Mycological properties The mycological properties of the 3543 strain are as follows.
1)形態
に3543株は顕微鏡下で、分枝した基中菌糸より比較
的長い、はぼまっすぐな気菌糸を形成し、輪生技は認め
られない。成熟した胞子鎖は20個以上の胞子のほぼま
っすぐな連鎖を認め、胞子の大きさは0.4〜0.6X
1.0〜1.3マイクロメ一タ位で、胞子の表面は平滑
である。1) Morphology: Under a microscope, strain 3543 forms straight aerial hyphae that are relatively longer than branched basal hyphae, and no whorling pattern is observed. A mature spore chain is an almost straight chain of 20 or more spores, and the spore size is 0.4 to 0.6X.
The surface of the spore is smooth, measuring 1.0 to 1.3 micrometers.
2) 各種培地における生育状態
(+)シュクロース・硝酸寒天培地
発育は中等度である。淡黄色の粉状の気菌糸を僅かに若
生し、溶解性色素は認められない。2) Growth status on various media (+) Sucrose/nitric acid agar medium Growth is moderate. Slightly young, pale yellow powdery aerial mycelium, with no soluble pigment observed.
(2)グルコース・アスパラギン寒天培地発育は僅かで
ある。淡黄色の粉状の気菌糸を中等度に着生し、溶解性
色素は認められない。(2) Growth on glucose-asparagine agar medium is slight. A moderate amount of pale yellow powdery aerial mycelium is observed, and no soluble pigment is observed.
(3)グリセリン−アスパラギン寒天培地(ISP−培
地5)
発育は中等度である。灰色のビロード状の気菌糸を良好
に着生し、黄褐色の溶解性色素を認める。(3) Glycerin-asparagine agar medium (ISP-medium 5) Growth is moderate. It has a good epiphyte of gray velvety aerial mycelium, and yellowish brown soluble pigment is observed.
(4)スターチ・無機塩寒天培地(ISP−培地4)発
育は良好である。黄褐灰色のビロード状の気菌糸を良好
に着生し、暗黄褐色の溶解性色素を認める。(4) Growth on starch/inorganic salt agar medium (ISP-medium 4) is good. It has a good epiphyte of yellow-brown-gray velvety aerial mycelium, and dark yellow-brown soluble pigment is observed.
(5)チロシン寒天培地(ISP−培地7)発育は良好
である。褐灰色の毛状の気菌糸を豊富に着生し、暗褐灰
色の溶解性色素を認める。(5) Growth on tyrosine agar medium (ISP-medium 7) is good. It is covered with abundant brownish-gray hair-like aerial mycelium, and dark brownish-gray soluble pigment is observed.
(8)栄養寒天培地
発育は僅かである。淡黄色の粉状の気菌糸を僅かに若生
17、暗褐灰色の溶解性色素を認める。(8) Growth on nutrient agar medium is slight. Slightly young, pale yellow powdery aerial mycelia with dark brownish-gray soluble pigments are observed.
(7)イースト・麦芽寒天培地(I SP−培地2)発
育は良好である。灰色のビロード状の気菌糸を良好に着
生し、暗視灰色の溶解性色素を認める。(7) Growth on yeast malt agar medium (ISP-medium 2) is good. It grows well with gray velvety aerial mycelium, and has a night vision gray soluble pigment.
3) 生理的性質
(I)ゼラチンの液化
グルコース・ペプトン・ゼラチン培地(27℃13りで
ゼラチンの液化が認められる。3) Physiological properties (I) Liquefaction of gelatin Glucose-peptone-gelatin medium (liquefaction of gelatin is observed at 27°C).
(2)スターチの加水分解
スターチ・無機塩寒天培地(27℃培養)でスターチの
加水分解が認められる。(2) Hydrolysis of starch Hydrolysis of starch is observed on starch/inorganic salt agar medium (cultured at 27°C).
(3)脱脂牛乳の凝固・ペプトン化(脱脂牛乳、27℃
培養)
明らかな凝固は認められず、ペプトン化が認められる。(3) Coagulation and peptonization of skim milk (skim milk, 27℃
Culture) No obvious coagulation was observed, and peptonization was observed.
(4)メラニン様色素の生成
ペプトン・イースト・鉄寒天培地およびトリプトン・イ
ースト液体培地でメラニン様色素の生成が認められる。(4) Production of melanin-like pigments The production of melanin-like pigments is observed in peptone-yeast-iron agar medium and tryptone-yeast liquid medium.
(5)炭素源の利用性(プリトノ\ム・ゴトリーブ寒天
培地1sP−培地9.27℃培養)
D−グルコース、L−アラビノース、D−キシロース、
ガラクトース、サリシンを利用して発育するが、シュク
ロース、D−フラクトース、ラフィノース、ラムノース
、イノシトール、D−マニトールはほとんど利用しない
。(5) Utilization of carbon source (Pritonom Gotlieb agar medium 1sP-medium 9.27°C culture) D-glucose, L-arabinose, D-xylose,
It grows using galactose and salicin, but hardly uses sucrose, D-fructose, raffinose, rhamnose, inositol, and D-mannitol.
(8)生育温度
10〜37℃で発育し、至適生育温度は27〜30℃あ
る(イースト・麦芽培地)。(8) It grows at a growth temperature of 10 to 37°C, and the optimum growth temperature is 27 to 30°C (yeast/malt medium).
20〜37℃で発育し、至適温度は20〜30℃である
(オートミール培地)。It grows at 20-37°C, and the optimum temperature is 20-30°C (oatmeal medium).
以上の性状を要約すると、K3543株はストレプトミ
セス(Streptomyecs)属に属し、なお、こ
の菌株の全菌体からエル型のジアミノピメリン酸(LL
−DAP)を検出、気菌糸はまっすぐでやや曲っており
、胞子鎖もまっすぐでやや曲っている。輪生技は認めら
れず、胞子の表面は平滑である。気菌糸は灰色を呈する
ことが多く、メラニン様色素をある種の培地で生成する
。班自分解能は脱脂牛乳の凝固は極めて弱いが、脱脂牛
乳のペプトン化およびゼラチンの液化性は中等程度であ
る。D−グルコース、L−アラビノース、D−キシロー
ス、ガラクトース、サリシンを利用するが、シュクロー
ス、D−フラクトース、ラフィノース、ラムノース、イ
ノシトール、D−マニトールはほとんど利用しない。To summarize the above characteristics, strain K3543 belongs to the genus Streptomyces, and all bacterial cells of this strain contain L-type diaminopimelic acid (LL).
-DAP) was detected, the aerial hyphae were straight and slightly curved, and the spore chains were also straight and slightly curved. No whorling is observed and the surface of the spores is smooth. Aerial mycelia are often gray in color and produce melanin-like pigments in certain media. Regarding the self-resolution ability, the coagulation of skim milk is extremely weak, but the peptonization of skim milk and the liquefaction of gelatin are moderate. D-glucose, L-arabinose, D-xylose, galactose, and salicin are used, but sucrose, D-fructose, raffinose, rhamnose, inositol, and D-manitol are hardly used.
以上の性状からすると、本菌株はストレプトミセス争タ
ナシェンシス(StrepLomyces Lanas
hien−sls )とほぼ一致するので、本発明者ら
は本菌株をストレプトミセス費タナシェンシス(st
repto−syces tanashiensis)
K 3543株と命名した。Judging from the above properties, this strain is StrepLomyces Lanashensis.
hien-sls), the present inventors identified this strain as Streptomyces tanashensis (st.
repto-syces tanashiensis)
It was named strain K3543.
本菌株は通商産業省工業技術院微生物工業技術研究所に
寄託されており、その微」二研受託番号は微工研菌寄第
9922号(FEMP−9922)である。This bacterial strain has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, and its microbiological laboratory accession number is FEMP-9922.
培養/ K 3543 R1の生産
化合物に3543R1は、ストレプトミセス属に属する
に3543R1生産菌を適当な培地で好気的に培養し、
培養物から目的物を採取することによって製造すること
ができる。Culture/K 3543R1 production compound 3543R1 is produced by culturing 3543R1-producing bacteria belonging to the genus Streptomyces aerobically in an appropriate medium,
It can be produced by collecting the target product from a culture.
培地は、K3543R1生産菌が利用しうる任意の栄養
源を含有するものでありうる。具体的には、例えば、炭
素源どしてグルコース、シュクロース、マルトース、ス
ターチおよび油詣類などが使用でき、窒素源として大豆
粉、綿実粕、乾燥酵母、酵母エキスおよびコーンステイ
ープリカーなどの有機物ならびにアンモニウム塩または
硝酸塩、たとえば硫酸アンモニウム、硝酸ナトリウムお
よび塩化アンモニウムなどの無機物が利用できる。The medium can contain any nutrient source that can be utilized by the K3543R1 producing bacteria. Specifically, for example, glucose, sucrose, maltose, starch, and oils can be used as carbon sources, and soybean flour, cottonseed meal, dried yeast, yeast extract, cornstarch liquor, etc. can be used as nitrogen sources. Organic and inorganic substances such as ammonium salts or nitrates such as ammonium sulfate, sodium nitrate and ammonium chloride are available.
また、必要に応じて、塩化ナトリウム、塩化カリウム、
燐酸塩、重金属塩など無機塩類を添加することができる
。発酵中の発泡を抑制するために、常法に従って適当な
消泡剤、例えばシリコン油を添加することもできる。In addition, if necessary, sodium chloride, potassium chloride,
Inorganic salts such as phosphates and heavy metal salts can be added. In order to suppress foaming during fermentation, suitable antifoaming agents such as silicone oil can also be added according to conventional methods.
培遣方法としては、一般に行われている抗生物質の生産
方法と同じく、好気的液体培養法が最も適している。培
養温度は20−37℃で適当であるが、25−30℃が
好ましい。この方法でに3543R1の生産量は、振旧
培養、通気攪拌培養ともに培養5日間で最高に達する。The most suitable culture method is the aerobic liquid culture method, which is the same as the commonly used antibiotic production method. A suitable culture temperature is 20-37°C, preferably 25-30°C. In this method, the production amount of 3543R1 reaches its maximum after 5 days of culture in both the shaking culture and aerated agitation culture.
このようにして、K3543R1の蓄積された培養物が
得られる。培養物中では、K3543R1はその一部は
菌体中に存在するが、その大部分は培養炉液中に存在す
る。In this way, an enriched culture of K3543R1 is obtained. In the culture, a part of K3543R1 exists in the bacterial cells, but most of it exists in the culture solution.
このような培養物からに3543R1を採取するには、
合目的的な任意の方法が利用可能である。To collect 3543R1 from such a culture,
Any suitable method can be used.
そのひとつの方法は抽出の原理に基くものであって、具
体的には、培養ン戸液中のK 3543 R1,につい
てはこれを水不混和性のに3543R1用溶媒(前記参
照)例えば酢酸エチルなどで抽出する方法、あるいは菌
体内のに3543R1については濾過、遠心分離などで
得た菌体集体をメタノール、エタノール、アセトンなど
で処理して回収する方法などがある。菌体を分離せずに
培養物そのままを上記の抽出操作に付すこともできる。One method is based on the principle of extraction, specifically, for K 3543 R1 in the culture solution, it is extracted with a water-immiscible solvent for 3543 R1 (see above), such as ethyl acetate. Alternatively, for 3543R1 inside the bacterial cells, there are methods of recovering bacterial cell aggregates obtained by filtration, centrifugation, etc., and treating them with methanol, ethanol, acetone, etc. The culture itself can also be subjected to the above extraction operation without separating the bacterial cells.
適当な溶媒を用いた向流分配法も抽出の範鴫に入れるこ
とができる。Countercurrent distribution methods using suitable solvents can also be included in the scope of extraction.
培養物からに3543R1を採取する他のひとつの方法
は吸着の原理に基くものであって、既に液状となってい
るに3543R1含有物、たとえば培養ン戸液あるいは
上記のようにして抽出操作を行うことによって得られる
抽出液、を対象として、適当な吸着剤、たとえばシリカ
ゲル、活性炭、「ダイヤイオンHP−20J (三菱
化成社製)などを用いて目的のに3543R1を吸着さ
せ、その後、適当な溶媒にて溶離させることによってに
3543R1を得ることができる。このようにして得ら
れたに3543R1溶液を減圧濃縮乾固すれば、K35
43R1粗標品がえら7ァ。Another method for extracting 3543R1 from cultures is based on the principle of adsorption, in which the 3543R1-containing material, which is already in liquid form, is extracted from the culture tank liquid or by the extraction procedure as described above. 3543R1 is adsorbed on the extract obtained by using a suitable adsorbent such as silica gel, activated carbon, Diaion HP-20J (manufactured by Mitsubishi Kasei Corporation), and then a suitable solvent is used to adsorb 3543R1. 3543R1 can be obtained by elution with K35.If the 3543R1 solution thus obtained is concentrated to dryness under reduced pressure, K35
43R1 cheap sample is the best.
このようにして得られるに3543R1の粗標品をさら
に精製するためには、上記の抽出法および吸希法にゲル
濾過法、^速液体クロマトグラフィーなどを必要に応じ
て組合せて必要回数行えばよい。たとえば、シリカゲル
などの吸着剤、「セファデックスLH−20J (フ
ァルマシア社製)などのゲル濾過剤を用いたカラムクロ
マトグラフィー、rYMcバック」 (山村科学社製)
などを用いた高速液体クロマトグラフィーおよび向流分
配法を適宜組合せて実施することができる。具体的には
、たとえば、K3543R1粗標品を[セ7ァデックス
LH−2OJカラムに付し、クロロホルム−メタノール
(I: 1)混合液で活性画分を溶出させ、濃縮乾固す
るとに3543R1の純品が得られる。In order to further purify the crude sample of 3543R1 obtained in this way, it is necessary to combine the above-mentioned extraction method and dilution method with gel filtration method, fast liquid chromatography, etc. as many times as necessary. good. For example, an adsorbent such as silica gel, column chromatography using a gel filtration agent such as Sephadex LH-20J (manufactured by Pharmacia), rYMc bag (manufactured by Yamamura Kagaku)
High-performance liquid chromatography using, for example, and a countercurrent distribution method can be carried out in appropriate combination. Specifically, for example, a crude sample of K3543R1 was applied to a Se7adex LH-2OJ column, the active fraction was eluted with a chloroform-methanol (I:1) mixture, and when concentrated to dryness, pure 3543R1 was obtained. Goods can be obtained.
K3543R1の用途
本発明による化合物に3543R1は、抗U瘍活性を有
するという点で有用である。Uses of K3543R1 3543R1 is a useful compound according to the present invention in that it has anti-U tumor activity.
生物活性
に3543R1はMl瘍細胞に対して細胞増殖抑制活性
を示した。たとえばマウスB16メラノーマ細胞を5X
]、04個/mlとなるように10%熱非働化仔牛血清
を含むRPMI 1640培地に浮遊させ、種々の濃
度のに3543R1とともに37℃で2日間培養した後
のIC5o値は、0.6μg / mlであった。Regarding biological activity, 3543R1 showed cytostatic activity against Ml tumor cells. For example, mouse B16 melanoma cells were
], the IC5o value was 0.6 μg/ml after being suspended in RPMI 1640 medium containing 10% heat-inactivated calf serum and incubated with various concentrations of 3543R1 at 37°C for 2 days. It was ml.
上記のように、本発明のに3543R]は抗腫瘍性を示
すことが明らかにされた。したがって、本発明のに35
43R1は抗腫瘍剤と17で使用することができる。As mentioned above, it was revealed that the drug 3543R of the present invention exhibits antitumor properties. Therefore, in the present invention, 35
43R1 can be used as an anti-tumor agent 17.
抗腫瘍剤
このように、本発明のに3543R1は、動物の腫瘍、
特に悪性腫瘍、に対して抗腫瘍性を示すことが明らかに
された。Antitumor agent Thus, 3543R1 of the present invention can be used to treat animal tumors,
It has been revealed that it exhibits antitumor properties, especially against malignant tumors.
従って、本発明化合物は抗M1瘍剤ないし腫瘍治療剤と
して使用することができる。Therefore, the compounds of the present invention can be used as anti-M1 tumor agents or tumor therapeutic agents.
抗腫1剤としての本発明化合物は合目的的な任意の投与
経路で、また採用投与経路によって決まる剤型で、投与
することができる。薬剤としては、製薬上許容される担
体ないし希釈剤で希釈された形態が普通である。The compound of the present invention as an antitumor agent can be administered by any convenient route of administration and in a dosage form determined by the route of administration employed. The drug is usually in a diluted form with a pharmaceutically acceptable carrier or diluent.
抗腫瘍剤として本発明化合物を実際に投与する場合には
、これを注射用蒸溜水または生理食塩水に溶解して注射
する方法が代表的なものの一つとして挙げられる。具体
的には、動物の場合には腹腔的注射、皮下注射、静脈ま
たは動脈への血管内注射および局所投与などの注射によ
る方法が、ヒトの場合は静脈または動脈への血管内注射
または局所投与などの注射による方法がある。When actually administering the compound of the present invention as an antitumor agent, one typical method is to dissolve the compound in distilled water for injection or physiological saline and inject it. Specifically, in the case of animals, injection methods such as intraperitoneal injection, subcutaneous injection, intravascular injection into a vein or artery, and local administration are used, and in the case of humans, intravascular injection into a vein or artery or local administration. There are injection methods such as
本発明化合物の投与量は、動物試験の結果および秤々の
状況を勘案して、連続的または間欠的に投与したときに
総投与量が一定量を越えないように定められる。具体的
な投与量は、投与方法、患者または被処理動物の状況、
例えば年齢、体重、性別、感受性、食餌、投与時間、併
用する薬剤、患者またはその病気の程度に応じて変化す
ることはいうまでもなく、また一定の条件のもとにおけ
る適量と投与回数は、上記指針を基として専門医の適量
決定試験によって決定されなければならない。具体的に
は、成人1日当り遊離塩基として0、 1〜1,5g程
度である。The dosage of the compound of the present invention is determined in consideration of the results of animal tests and the weighing conditions so that the total dosage does not exceed a certain amount when administered continuously or intermittently. The specific dosage depends on the administration method, the situation of the patient or treated animal,
For example, it goes without saying that the appropriate amount and frequency of administration under certain conditions will vary depending on age, weight, sex, sensitivity, diet, administration time, concomitant drugs, patient and degree of disease. The appropriate dosage must be determined through a test conducted by a specialist based on the above guidelines. Specifically, it is about 0.1 to 1.5 g of free base per day for an adult.
実験例 以下において「%」はrw/v%」である。Experimental example In the following, "%" means "rw/v%".
実施例
1)種母の調製
使用した培地は、下記の組成の成分を1リットルの水に
溶解してpu7.2に調整したものである。Example 1) Preparation of Seed Mother The medium used was prepared by dissolving the following components in 1 liter of water and adjusting the PU to 7.2.
グルコース 0.4g
麦芽エキス 1.0g
酵母エキス 0.4g
上記培地100m1を500m1のイボ付三角フラスコ
へ分注し、殺m後、ストレプトミセス−タナシェンシス
に3543株(FERM P−9922)をスラント
より1白金耳接種し、27℃にて2日間振盪培養したも
のを種母とした。Glucose 0.4g Malt extract 1.0g Yeast extract 0.4g 100ml of the above medium was dispensed into a 500ml Erlenmeyer flask with warts, and after killing, 3543 strain (FERM P-9922) was added to Streptomyces thanashensis from a slant. The seed mother was inoculated with a platinum loop and cultured with shaking at 27°C for 2 days.
2)培養
使用した培地は、下記の組成の成分を1リツトルの水に
溶解して、pH7,4に調整したものである。2) The culture medium used was prepared by dissolving the following components in 1 liter of water and adjusting the pH to 7.4.
グリセロール 3.Og
魚粉 2.OK
炭酸カルシウム 0.2g
上記培地を25リツトルずつ50リツトル容ジャーファ
ーメンタ−に分注殺菌したものへ、上記種母300m1
を添加し、27℃にて5日間、20Orpm、0.4.
VVMの通気攪拌培養を行った。Glycerol 3. Og fishmeal 2. OK Calcium carbonate 0.2g Dispense 25 liters of the above medium into 50 liter jar fermenters and sterilize them, add 300ml of the above seed mother
was added and heated at 27° C. for 5 days, 20 Orpm, 0.4.
VVM was cultured with aeration and agitation.
3)K3543R1の採取
上記の条件で培養後、培養液(50リツトル)を濾過し
、炉液をpH8,5にて等量の酢酸エチルで抽出する。3) Collection of K3543R1 After culturing under the above conditions, the culture solution (50 liters) is filtered, and the fermentation solution is extracted with an equal volume of ethyl acetate at pH 8.5.
抽出液を等量の0.01規定塩酸で逆転抽出した後、水
層をpH8,5に調整j2、さらに等量の酢酸エチルを
抽出し、濃縮乾固する。After reverse extraction of the extract with an equal volume of 0.01N hydrochloric acid, the aqueous layer was adjusted to pH 8.5, and an equal volume of ethyl acetate was extracted and concentrated to dryness.
これを100m1のクロロホルムに溶解し、不溶物を除
いた後、シリカゲル(和光純薬製「ワコーゲルC200
J)のカラム(4cmφX20cm)に吸着させ、クロ
ロホルム−メタノール(20:1)で溶出する。活性フ
ラクションを濃縮乾固するとに3543R1の赤色粉末
47mgを得る。After dissolving this in 100 ml of chloroform and removing insoluble matter, silica gel (Wako Pure Chemical's "Wako Gel C200"
J) column (4 cmφ x 20 cm) and elute with chloroform-methanol (20:1). The active fraction was concentrated to dryness to obtain 47 mg of red powder of 3543R1.
第1図は、K3543R1のメタノール中(実線)、0
.01規定塩酸−メタノール中(点線)および0.01
規定水酸化ナトリウム−メタノール中(破線)でのに3
543R1の紫外吸収スペクトルを模写したものである
。
第2図は、K3543R1のKBrディスク法による赤
外吸収スペクトルを模写したものである。
第3図は、K3543R1の重クロロホルム中における
500メガヘルツプロトン核磁気共鳴スペクトルを模写
したものである。
第4図は、K3543R1の重クロロホルム中における
125メガヘルツ炭1g13核磁気共鳴スペクトルを模
写したものである。
出願人代理人 佐 藝 −雄Figure 1 shows K3543R1 in methanol (solid line), 0
.. 01 N hydrochloric acid in methanol (dotted line) and 0.01
3 in normal sodium hydroxide-methanol (dashed line)
This is a reproduction of the ultraviolet absorption spectrum of 543R1. FIG. 2 is a reproduction of the infrared absorption spectrum of K3543R1 obtained by the KBr disk method. FIG. 3 is a reproduction of the 500 MHz proton nuclear magnetic resonance spectrum of K3543R1 in deuterated chloroform. FIG. 4 is a reproduction of the 125 MHz charcoal 1g13 nuclear magnetic resonance spectrum of K3543R1 in deuterated chloroform. Applicant's agent: Sae-O
Claims (1)
はその酸付加塩を有効成分とする抗腫瘍剤。 ▲数式、化学式、表等があります▼( I ) 3、ストレプトミセス属に属しK3543R1の生産能
を有する菌株を適当な培地で好気的に培養し、培養物よ
りK3543R1を得ることを特徴とする、次式( I
)で示されるK3543R1の製造法。 ▲数式、化学式、表等があります▼( I )[Claims] 1. A novel substance K3543R1 represented by the following formula (I) or an acid addition salt thereof. ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (I) 2. An antitumor agent containing the compound K3543R1 shown by the following formula (I) or its acid addition salt as an active ingredient. ▲Contains mathematical formulas, chemical formulas, tables, etc.▼ (I) 3. A strain belonging to the genus Streptomyces and capable of producing K3543R1 is cultured aerobically in an appropriate medium, and K3543R1 is obtained from the culture. , the following formula (I
) Production method of K3543R1 shown in ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11978688A JPH01290673A (en) | 1988-05-17 | 1988-05-17 | Novel substance k3543r1, its use and production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11978688A JPH01290673A (en) | 1988-05-17 | 1988-05-17 | Novel substance k3543r1, its use and production |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01290673A true JPH01290673A (en) | 1989-11-22 |
Family
ID=14770189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11978688A Pending JPH01290673A (en) | 1988-05-17 | 1988-05-17 | Novel substance k3543r1, its use and production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01290673A (en) |
-
1988
- 1988-05-17 JP JP11978688A patent/JPH01290673A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3111470B2 (en) | Novel polypeptide compound and method for producing the same | |
JPH01290673A (en) | Novel substance k3543r1, its use and production | |
JPH01246288A (en) | Tan-1030a and its derivative, production and use thereof | |
JPS6212227B2 (en) | ||
JPH02221292A (en) | New substance 02-3, its use and production thereof | |
JP2706843B2 (en) | Novel anthraquinone derivative, method for producing the same, and antitumor agent containing the derivative | |
JP3066166B2 (en) | Novel compound HC34, its use and production | |
JPH08239379A (en) | Kr 2827 derivative as new substance, its production and use | |
JPH0367077B2 (en) | ||
JPH0259596A (en) | Novel substance, utilization and production thereof | |
JPS623789A (en) | Antibiotic substance tokimycin a and production thereof | |
JPH0449277A (en) | Novel substance cc12 | |
JPS63157992A (en) | Antibiotic substance n-hydroxydihydroabikoviromycin | |
JPS6025999A (en) | Anthracyclin compound ag-2 and its use | |
JPH01265893A (en) | Novel substance k3619, use and production thereof | |
JPH0495069A (en) | New bioactive substance ec 40 | |
JPS63203676A (en) | Novel substance kr2827 | |
JPS6281398A (en) | Anthracycline compound and use thereof | |
JPH04316573A (en) | New compound cf-24, its use and production | |
JPS60202896A (en) | Anthracyclin compound, argomycin derivative and use thereof | |
JPH0585998A (en) | New compounds ca39-a and ca39-b, their use and production | |
JPH0631280B2 (en) | WS7739 substance and its manufacturing method | |
JPH03232887A (en) | New substance bk 97, use thereof and production thereof | |
JPH02286683A (en) | Novel substance dt136 and its production | |
JPH02229189A (en) | Novel substance inostamycin, its use and production thereof |